TABLE 2

Single-SNP tests of association with type 2 diabetes–end-stage renal disease

GeneSNPEuropean reported risk alleleAfrican American subject data
Reported European subject data
Power to detect association in African Americans
Risk allele frequency in control subjectsRisk allele frequency in case subjectsAdditive PAdmixture-adjusted additive PAdmixture-adjusted OR (95% CI)Reported risk allele frequency in control subjectsReported risk allele frequency in case subjectsReported OR (95% CI)α = 0.05α = 0.10
PKN2rs6698181T0.1530.1560.8290.3881.08 (0.91–1.29)0.2900.3201.11 (1.05–1.16)0.2370.345
IGF2BP2rs4402960T0.5250.5280.8650.8030.98 (0.87–1.11)0.3040.3411.18 (1.08–1.28)0.5550.675
FLJ39370rs17044137A0.3290.3260.8540.7470.98 (0.86–1.12)0.2300.2701.13 (1.06–1.19)0.0600.115
CDKAL1rs10946398C0.5820.6150.0290.1101.11 (0.98–1.26)0.3190.3611.16 (1.10–1.22)0.4270.522
CDKAL1rs7754840C0.5850.6160.0390.1361.10 (0.97–1.25)0.3600.3871.12 (1.03–1.22)0.4270.552
SLC30A8rs13266634C0.9140.9160.8610.5431.46 (0.43–4.89)0.6090.6491.18 (1.09–1.29)0.1690.263
CDKN2B/CDKN2Ars564398T0.9340.9430.1960.3202.99 (0.34–25.98)0.5580.5951.13 (1.08–1.19)0.1400.225
CDKN2B/CDKN2Ars10811661T0.9330.9270.4120.1280.18 (0.02–1.64)0.8500.8721.20 (1.07–1.36)0.3040.422
IDE/KIF11/HHEXrs1111875C0.7660.7740.5470.7671.02 (0.88–1.19)0.5220.5461.10 (1.01–1.19)0.3710.495
IDE/KIF11/HHEXrs5015480C0.6330.6210.4120.4000.95 (0.83–1.08)0.4250.3791.13 (1.08–1.17)0.4700.595
IDE/KIF11/HHEXrs7923837G0.9170.9290.1430.3031.87 (0.57–6.12)0.5970.6221.11 (1.02–1.20)0.1430.229
Intragenicrs9300039C0.8890.8840.6180.0290.42 (0.19–0.91)0.8920.9241.48 (1.28–1.71)0.5840.701
LOC387761rs7480010G0.8580.8900.0020.0841.18 (0.98–1.44)0.3010.3361.14 (1.01–1.27)0.0620.117
EXT2/ALX4rs1113132C0.9150.9200.5790.2210.47 (0.14–1.57)0.7330.7631.15 (0.88–1.42)0.4750.600
EXT2/ALX4rs11037909T0.8620.8590.7680.5110.94 (0.79–1.13)0.7290.7601.27 (0.97–1.57)0.9130.953
EXT2/ALX4rs3740878A0.9070.9140.4150.1290.46 (0.17–1.26)0.7280.7601.26 (0.97–1.55)0.7600.846
FTOrs8050136A0.4460.4520.6860.7831.02 (0.90–1.15)0.3980.4551.23 (1.18–1.32)0.7110.808
TCF7L2*rs7903146T0.2840.3541.73 × 10−61.59 × 10−61.39 (1.21–1.60)0.1810.2271.37 (1.31–1.43)0.9970.999
  • *

    * Power analysis for TCF7L2 was calculated using a population of 960 case and 1,000 control subjects.

  • SNPs have minor allele homozygote counts <10 in the case or control population, and dominant model P values and ORs are reported. Data in bold are P values <0.05 and corresponding ORs. European risk allele frequencies and ORs were obtained from recent WGA studies (refs. 16).